Family Offices Boost Life Sciences Partners’s Over-Subscribed Fifth Fund
Family offices are increasing their exposure to Europe’s life sciences sector by investing in venture capital funds, including the just-closed over-subscribed fifth fund from Life Sciences Partners.
You may also be interested in...
Even Series A rounds have been large during recent record-breaking years for biotech venture capital investment, but it looks like smaller financings for early-stage companies may be in the midst of a comeback. With VC firms closing new funds, that raises the question: Will the number of preclinical and Phase I financings increase?
Forbion Capital Partners has conducted the final closing of its third main fund Forbion Capital Fund III (FCF III), raising a total of €183m. Despite the Netherlands-based venture firm closing its last fund - FCF II - in 2010 when the investment climate was less friendly, Forbion's investment strategy remains much the same. Managing partner Sander Slootweg explains why.
AstraZeneca plc, GlaxoSmithKline plc and Johnson & Johnson are investing £30m between them into a new fund aimed at advancing academic therapeutic research from three leading universities.